Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.52 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FBP1 | P09467 | 2/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613838 | 0.87 | FBP1 (0.51) | LMNATP53NPC1RAB9AMEN1 | |
| SCHEMBL5091405 | 0.86 | TP53 (0.64) | LMNATP53ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL8125417 | 0.86 | SCD (0.64) | LMNATP53NPC1RAB9AMEN1 | |
| SCHEMBL13148268 | 0.82 | HPGDS (0.62) | LMNAALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL11434478 | 0.79 | HDAC1 (0.60) | LMNATP53MEN1KMT2AFBP1 | |
| SCHEMBL3768774 | 0.78 | PTGES (0.60) | LMNATP53CETPMAPT | |
| SCHEMBL3777315 | 0.76 | KCNH2 (0.63) | LMNANPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL14537898 | 0.76 | FBP1 (0.50) | LMNATP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14047971 | 0.75 | FFAR2 (0.60) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL18851597 | 0.74 | MAPT (0.50) | LMNANPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | LMNA 1345/4885TP53 2351/4885NPC1 639/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | LMNA 1466/4885TP53 2530/4885NPC1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.